In this file:
· Does Dicamba Have a Future?
· Roundup Maker to Pay $10 Billion to Settle Cancer Suits
Does Dicamba Have a Future?
By Gary Truitt, Hoosier Ag Today
Jun 24, 2020
A federal court has instructed the EPA to withdraw the registration of dicamba weed control products. What does that mean for one of the only weed control options farmers have for some resistant weeds?
Purdue weed specialist Bill Johnson says there is a chance farmers will have a new dicamba formulation for 2021.
“We are currently doing research on some of the new dicamba formulations the companies have developed. These new products address the off target movement and should be an improvement. They intend to apply for registration for 2021.”
He added that, if approved, farmers will have a product to use next growing season.
Dicamba tolerant seeds are not affected, and there will be plenty to plant next year.
However, whether the herbicide can be used to control resistant weeds like marestail, water hemp, and giant ragweed in those fields is still unknown.
Roundup Maker to Pay $10 Billion to Settle Cancer Suits
Bayer faced tens of thousands of claims linking the weedkiller to cases of non-Hodgkin’s lymphoma. Some of the money is set aside for future cases.
By Patricia Cohen, The New York Times
June 24, 2020
When Bayer, the giant German chemical and pharmaceutical maker, acquired Monsanto two years ago, the company knew it was also buying the world’s best-known weedkiller. What it didn’t anticipate was a legal firestorm over claims that the herbicide, Roundup, caused cancer.
Now Bayer is moving to put those troubles behind it, agreeing to pay more than $10 billion to settle tens of thousands of claims while continuing to sell the product without adding warning labels about its safety.
The deal, announced Wednesday, is among the largest settlements ever in U.S. civil litigation. Negotiations were extraordinarily complex, producing separate agreements with 25 lead law firms whose clients will receive varying amounts.
“It’s rare that we see a consensual settlement with that many zeros on it,” said Nora Freeman Engstrom, a professor at Stanford University Law School.
Bayer, which inherited the litigation when it bought Monsanto for $63 billion, has repeatedly maintained that Roundup is safe.
Most of the early lawsuits were brought by homeowners and groundskeepers, although they account for only a tiny portion of Roundup’s sales. Farmers are the biggest customers, and many agricultural associations contend glyphosate, the key ingredient in Roundup, is safe, effective and better than available alternatives.
The settlement covers an estimated 95,000 cases and includes $1.25 billion for potential future claims from Roundup customers who may develop the form of cancer known as non-Hodgkin’s lymphoma.
The company is taking a calculated risk that the benchmark settlement will largely resolve its legal problems. Bayer still faces at least 30,000 claims from plaintiffs who have not agreed to join the settlement.
Werner Baumann, Bayer’s chief executive, said that the two critical conditions for a settlement were that it was financially reasonable and that it would bring closure to the litigation.
“We are totally convinced” this does both, Mr. Baumann said in an interview on Wednesday. There is money put aside for existing claimants outside of the agreement, he said, and a structure to deal with future claimants that could emerge.
Fletch Trammell, a Houston-based lawyer who said he represented 5,000 claimants who declined to join, disagreed. “This is nothing like the closure they’re trying to imply,” he said. “It’s like putting out part of a house fire.”
But Kenneth R. Feinberg, the Washington lawyer who oversaw the mediation process, said...
more, including links